Brokerages expect Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) to post sales of $77.31 million for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Pacira Pharmaceuticals’ earnings. The lowest sales estimate is $75.30 million and the highest is $82.32 million. Pacira Pharmaceuticals reported sales of $70.93 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 9%. The firm is scheduled to announce its next earnings results on Wednesday, August 1st.
According to Zacks, analysts expect that Pacira Pharmaceuticals will report full-year sales of $316.11 million for the current year, with estimates ranging from $311.22 million to $329.62 million. For the next year, analysts expect that the company will post sales of $366.28 million per share, with estimates ranging from $343.00 million to $412.19 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 3rd. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. Pacira Pharmaceuticals had a negative net margin of 11.45% and a negative return on equity of 5.81%. The business had revenue of $74.61 million during the quarter, compared to the consensus estimate of $73.92 million. During the same quarter in the previous year, the firm earned ($0.19) EPS. The company’s revenue was up 7.7% compared to the same quarter last year.
Pacira Pharmaceuticals stock traded up $0.25 during trading hours on Monday, reaching $34.85. 11,546 shares of the stock were exchanged, compared to its average volume of 1,084,334. The company has a market cap of $1.37 billion, a P/E ratio of -60.60 and a beta of 1.77. The company has a debt-to-equity ratio of 1.00, a quick ratio of 7.83 and a current ratio of 8.66. Pacira Pharmaceuticals has a 52-week low of $33.85 and a 52-week high of $35.60.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC grew its stake in Pacira Pharmaceuticals by 64.6% in the 1st quarter. Millennium Management LLC now owns 888,391 shares of the company’s stock valued at $27,673,000 after acquiring an additional 348,542 shares during the last quarter. Nexthera Capital LP acquired a new stake in Pacira Pharmaceuticals in the 1st quarter valued at about $14,909,000. PointState Capital LP grew its stake in Pacira Pharmaceuticals by 71.1% in the 1st quarter. PointState Capital LP now owns 2,038,153 shares of the company’s stock valued at $63,488,000 after acquiring an additional 847,146 shares during the last quarter. Guggenheim Capital LLC grew its stake in Pacira Pharmaceuticals by 21.4% in the 1st quarter. Guggenheim Capital LLC now owns 68,706 shares of the company’s stock valued at $2,141,000 after acquiring an additional 12,112 shares during the last quarter. Finally, venBio Select Advisor LLC grew its stake in Pacira Pharmaceuticals by 102.1% in the 1st quarter. venBio Select Advisor LLC now owns 1,715,072 shares of the company’s stock valued at $53,424,000 after acquiring an additional 866,500 shares during the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.